文献速递免疫规划妇幼与学校卫生

接种Cervarix®或Gardasil®疫苗后长达7年针对疫苗型(HPV6/11/16/18)和非疫苗型(HPV31/33/45/52/58)HPV抗原的结合抗体水平

Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine.
PubMed 文献 · Vaccine · 2022-02-01

研究评估12-15岁女孩按三剂程序接种双价(Cervarix®)或四价(Gardasil®)HPV疫苗后长达7年针对疫苗型(HPV6/11/16/18)和非疫苗型(HPV31/33/45/52/58)抗原的抗体广度、幅度和持久性。疫苗型抗体水平在7年随访期内下降,但仍至少比自然感染典型抗体水平高一个数量级;非疫苗型血清阳性率仍高,但抗体水平接近自然感染后水平。

要点

  • 疫苗型抗体7年内下降但仍至少高于自然感染抗体水平一个数量级
  • 非疫苗型血清阳性率7年时仍高但抗体水平接近自然感染水平
  • 免疫应答的广度、幅度、特异性和持久性数据支持HPV疫苗公共卫生干预

核心结论

  • 疫苗型抗体水平在7年随访期内下降,但仍至少比自然感染典型抗体水平高一个数量级。
  • 非疫苗型血清阳性率在初次接种7年后仍高,但抗体水平接近自然感染后典型水平。

研究设计与样本

  • 评估12-15岁女孩按三剂程序接种双价(Cervarix®)或四价(Gardasil®)HPV疫苗后长达7年针对疫苗型(HPV6/11/16/18)和非疫苗型(HPV31/33/45/52/58)HPV抗原的结合抗体水平。

主要发现

  • 疫苗型抗体水平在7年随访期内下降,但仍至少比自然感染典型抗体水平高一个数量级。
  • 非疫苗型血清阳性率在初次接种7年后仍高,但抗体水平接近自然感染后典型水平。

临床怎么用

  • 原文未据此给出推荐,仅指出免疫应答的广度、幅度、特异性和持久性经验数据有助于改善支持该公共卫生干预的证据基础。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human Papillomavirus (HPV) bivalent (Cervarix®) and quadrivalent (Gardasil®) vaccines demonstrate robust efficacy against vaccine types and cross-protection against related non-vaccine types. Here we evaluate the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection. Vaccine-type antibody levels waned over the 7-year follow up period but remained at least an order of magnitude above the typical antibody levels elicited by natural infection. Seropositivity to non-vaccine types remained high 7 years after initial vaccination, but antibody levels approached those typically generated following natural infection. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Panwar K, Godi A, Cocuzza CE, et al. Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine. 2022. PMID: 35115194. doi:10.1016/j.vaccine.2022.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。